Moleculin Biotech
MBRX
18 hedge funds and large institutions have $10.9M invested in Moleculin Biotech in 2021 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, reducing their positions, and 5 closing their positions.
541% more capital inflows, than outflows
Capital inflows: $3.38M | Capital outflows: $528K
2.9% more ownership
Funds ownership: 7.57% → 10.47% (+2.9%)
0% more funds holding
Funds holding: 18 → 18 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.13M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$246K |
| 3 |
State Street
Boston,
Massachusetts
|
+$218K |
| 4 |
Sio Capital Management
New York
|
+$164K |
| 5 |
BlackRock
New York
|
+$136K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
-$136K |
| 2 |
Squarepoint
New York
|
-$118K |
| 3 |
Two Sigma Securities
New York
|
-$111K |
| 4 |
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$109K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$50K |
MBRX Hedge Fund Activity: Q2 2021 in Review
18 of the 5,769 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q2 2021, worth a combined $10.9M — up 23% from $8.88M a quarter earlier.
Fund positioning in MBRX was balanced in Q2 2021: 5 funds opened new positions, 5 closed out, 6 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Group, adding an estimated $2.13M. The largest seller was Harel Insurance Investments & Financial Services, exiting entirely with an estimated $136K sold.
- 18 institutional investors held Moleculin Biotech (MBRX) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $10.9M of Moleculin Biotech stock for Q2 2021, up 23% quarter-over-quarter.
- 5 funds opened new Moleculin Biotech positions in Q2 2021 and 5 closed out, a net change of 0 holders.
- The largest Moleculin Biotech buyer in Q2 2021 was Vanguard Group, an estimated $2.13M added.
- The largest Moleculin Biotech seller in Q2 2021 was Harel Insurance Investments & Financial Services, an estimated $136K sold.
Based on aggregated 13F filings for Q2 2021.